These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 15152628)

  • 1. FDA publishes analysis of the pipeline problem.
    Frantz S
    Nat Rev Drug Discov; 2004 May; 3(5):379. PubMed ID: 15152628
    [No Abstract]   [Full Text] [Related]  

  • 2. FDA appointee faces angry, demoralized staff.
    Fox JL
    Nat Biotechnol; 2002 Nov; 20(11):1065. PubMed ID: 12410237
    [No Abstract]   [Full Text] [Related]  

  • 3. Teaching the elephant to dance: privatizing the FDA review process.
    Price EC
    Food Drug Law J; 1996; 51(4):651-76. PubMed ID: 11797734
    [No Abstract]   [Full Text] [Related]  

  • 4. An FDA perspective on the drug development process.
    Woodcock J
    Food Drug Law J; 1997; 52(2):145-50. PubMed ID: 10557550
    [No Abstract]   [Full Text] [Related]  

  • 5. The FDA: a dromedary tale.
    Nat Biotechnol; 1997 Jan; 15(1):1. PubMed ID: 9035089
    [No Abstract]   [Full Text] [Related]  

  • 6. 2010 FDA drug approvals.
    Mullard A
    Nat Rev Drug Discov; 2011 Feb; 10(2):82-5. PubMed ID: 21283092
    [No Abstract]   [Full Text] [Related]  

  • 7. Will FDA relinquish the "gold standard" for new drug approval? Redefining "substantial evidence" in the FDA Modernization Act of 1997.
    Kulynych J
    Food Drug Law J; 1999; 54(1):127-49. PubMed ID: 11758555
    [No Abstract]   [Full Text] [Related]  

  • 8. Remarks by the Commissioner of Food and Drugs.
    Kessler DA
    Food Drug Law J; 1996; 51(2):207-15. PubMed ID: 11817358
    [No Abstract]   [Full Text] [Related]  

  • 9. FDA embraces risk-management approach.
    Fox JL
    Nat Biotechnol; 2003 Oct; 21(10):1120-1. PubMed ID: 14520383
    [No Abstract]   [Full Text] [Related]  

  • 10. The ODAC Chronicles: Part 4. Hurdles pre and post accelerated approval.
    Grillo-López AJ
    Expert Rev Anticancer Ther; 2005 Apr; 5(2):197-200. PubMed ID: 15877516
    [No Abstract]   [Full Text] [Related]  

  • 11. FDA: friend or foe?
    Lewis TS
    Med Device Technol; 1996 Nov; 7(9):24-30. PubMed ID: 10163675
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reform bill to speed drugs to residents.
    Hawryluk M
    Provider; 1997 Nov; 23(11):37-8. PubMed ID: 10173669
    [No Abstract]   [Full Text] [Related]  

  • 13. Regulatory watch: FDA guidance on co-developing investigational drugs.
    Nat Rev Drug Discov; 2011 Feb; 10(2):86. PubMed ID: 21283094
    [No Abstract]   [Full Text] [Related]  

  • 14. Vision and will: the future of the FDA.
    Epstein D
    Oncologist; 2009 Apr; 14(4):317-9. PubMed ID: 19365098
    [No Abstract]   [Full Text] [Related]  

  • 15. Remarks of the Lead Deputy Commissioner of the Food and Drug Administration.
    Friedman MA
    Food Drug Law J; 1998; 53(1):19-23. PubMed ID: 11795333
    [No Abstract]   [Full Text] [Related]  

  • 16. FDA shortened drug approval time in 1995.
    Public Health Rep; 1996; 111(4):290. PubMed ID: 8711090
    [No Abstract]   [Full Text] [Related]  

  • 17. Changes in FDA drug classification and priority review policy.
    Crawford SY
    Am J Hosp Pharm; 1992 Oct; 49(10):2383, 2386. PubMed ID: 1442812
    [No Abstract]   [Full Text] [Related]  

  • 18. FDA starts moving on critical path, but initiative running out of steam.
    Finkelstein JB
    J Natl Cancer Inst; 2007 Mar; 99(6):426-7. PubMed ID: 17374831
    [No Abstract]   [Full Text] [Related]  

  • 19. Working together to enhance the efficiency of medical product development.
    Sanhai WR
    J Nucl Med; 2008 Jun; 49(6):43N-45N. PubMed ID: 18511823
    [No Abstract]   [Full Text] [Related]  

  • 20. FDA begins product approval initiative.
    Lewis C
    FDA Consum; 2003; 37(3):10-1. PubMed ID: 12793386
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.